Impact Factor 3.552

The 2nd most cited open-access journal in Clinical Neurology

General Commentary ARTICLE

Front. Neurol., 12 August 2013 | https://doi.org/10.3389/fneur.2013.00113

West syndrome treatment: new roads for an old syndrome

Piero Pavone1, Raffaele Falsaperla1, Martino Ruggieri2, Andrea Domenico Praticò1 and Lorenzo Pavone1*
  • 1Unit of Pediatrics and Pediatrics Emergency, University Hospital “Vittorio Emanuele,”, Catania, Italy
  • 2Department of Educational Sciences, University of Catania, Catania, Italy

A commentary on

West syndrome: response to valproate
by Chandra, S., Bhave, A., Bhargava, R., Kumar, C., and Kumar, R. (2012). Front. Neurol. 3:166. doi: 10.3389/fneur.2012.00166

The recent article by Chandra et al. (1), published in Frontiers in Neurology, on the treatment of West syndrome (WS) by using valproate as monotherapy, prompted us to rethink about the past and present treatment strategies and the outcome in this severe epileptic syndrome.

Even though the study by Chandra et al. (1) leaves some unsolved issues regarding the lack of demonstration of hypsarrhythmia in 70% of their cases, the long-term follow-up of cognitive profiles in the whole group, an extensive etiological work-up and the alternative use of new therapeutic drugs such as vigabatrin, it provides the scientific community with successful short-term results in 36/91 (40%) of their treated WS patients who showed “…a greater than 80% decrease in the number of spasms or complete cessation.”

Historically, some previous studies in children with WS, which employed valproate as monotherapy, proved effective in controlling either hypsarrhythmia and/or the epileptic spasms (26). Besides valproate, zonisamide, topiramate, and nitrazepam (as monotherapy or in combination) showed good responses (ranging from 20 to 35% of treated patients) in WS (79). More effective, however, has proven the short-term treatment with hormonal therapy (i.e., by using the adrenocorticotropic hormone ACTH), which has been reported to succeed in 60–80% of the infants with WS treated (10). Therefore, nowadays the first-line treatment of WS and more in general of infantile spasms includes ACTH as well as vigabatrin (the latter being effective especially in infantile spasms in the setting of tuberous sclerosis) (1113). Therefore, most recently the treatment of WS with valproate has been overtaken and overlooked (14, 15).

Overall, the treatment strategies in WS [either the first-line treatments (e.g., ACTH and vigabatrin) or the more classical non-golden treatments (e.g., valproate or other newer anticonvulsants)] are based on the assumption that an early initiation of therapy coupled with a rapid control of seizures in these patients may prevent the arrest or the decline in cognitive development.

However, the spectrum of disorders associated to clinical spasms with onset in infancy is wider than previously thought and is currently comprised under the umbrella term of Infantile Spasms syndrome (ISs), which defines an epileptic syndrome (occurring in children younger than 1 year – rarely older than 2 years), with clinical (epileptic: i.e., associated to an epileptiform EEG) spasms usually occurring in clusters whose most characteristic EEG finding is hypsarrhythmia (the spasms are often associated with developmental arrest or regression). WS refers to a form (a subset) of ISs, characterized by the combination of clustered spasms and hypsarrhythmia on an EEG. Additional (less common) phenotypes falling within the ISs include the so-called infantile spasms single-spasm variant (ISSV: in which spasms may occur singly rather than in clusters), hypsarrhythmia without infantile spasms [HWIS: in which hypsarrhythmia can be (incidentally) recorded without any evidence of clinical spasms], and infantile spasms without hypsarrhythmia (ISW: in which typical clinical spasms may manifest in absence of hypsarrhythmia) [reviewed in Lux and Osborne (11)]. There is a growing evidence that ISs and related phenotypes may result, besides from acquired events, from disturbances in key genetic pathways of brain development: specifically, in the gene regulatory network of GABAergic forebrain dorsal-ventral development, and abnormalities in molecules expressed at the synapse (16). Notably, children with these genetic associations also have phenotypes beyond epilepsy, including dysmorphic features, autism, movement disorders, and systemic malformations (16). In this respect, the ISs and related phenotypes, could be regarded as a (peculiar) type of neurological manifestation underlying the involvement of many different neuronal/interneuronal networks and, accordingly, the cognitive delay or arrest regarded as a (genetically predetermined) part of the (more or less severe) phenotype, which in turn is related to the type or severity of mutation or to the protein/molecule and/or regulatory network involved.

For all the above reasons, the results of Chandra et al. (1) highlight the multifaceted aspects of the spectrum of disorders associated to clinical spasms (i.e., good response to a classical anticonvulsant in the era of newer drugs and other-than valproate first-line treatments) and the prevalent role that etiological events could play in pre-programing the cognitive and behavioral outcomes in the setting of ISs (16). In this respect, without forgetting the current first-line treatment strategies for ISs and related phenotypes, we should also look with less strict therapeutic boundaries at patients with clinical spasms as in the near future the gold standard could be the development of new therapies (with new or old molecules) that simply target specific pathways of pathogenesis, as currently occurs in tuberous sclerosis (17, 18).

References

1. Chandra S, Bhave A, Bhargava R, Kumar C, Kumar R. West syndrome: response to valproate. Front Neurol (2012) 3:166. doi:10.3389/fneur.2012.00166

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

2. Pavone L, Incorpora G, La Rosa M, Li Volti S, Mollica F. Treatment of infantile spasms with sodium dipropylacetic acid. Dev Med Child Neurol (1981) 23:454–61. doi:10.1111/j.1469-8749.1981.tb02018.x

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

3. Dyken PR, Du Rant RH, Minden DB, King DW. Short term effects of valproate on infantile spasms. Pediatr Neurol (1985) 1:34–7. doi:10.1016/0887-8994(85)90006-2

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

4. Seimes H, Spohr HL, Michael T, Nau H. Therapy of infantile spasms with valproate: results of a prospective study. Epilepsia (1988) 29:553–60. doi:10.1111/j.1528-1157.1988.tb03760.x

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

5. Pratz JM, Garaizar C, Rua MJ, Garcia-Nieto ML, Madoz P. Infantile spasms treated with high doses of sodium valproate: initial response and follow-up. Dev Med Child Neurol (1991) 33:617–25. doi:10.1111/j.1469-8749.1991.tb14932.x

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

6. Ohtsuka Y, Amano R, Mizukawa M, Oka E, Ohtahara S. Treatment of intractable childhood epilepsy with high dose valproate. Epilepsia (1992) 33:158–64. doi:10.1111/j.1528-1157.1992.tb02300.x

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

7. Chamberlain MC. Nitrazepam for refractory infantile spasms the Lennox-Gastaut syndrome. J Child Neurol (1996) 11:31–4. doi:10.1177/088307389601100107

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

8. Suzuki Y. Zonisamide in West syndrome. Brain Dev (2001) 23:658–61. doi:10.1016/S0387-7604(01)00301-1

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

9. Hosain SA, Merchant S, Solomon GE, Chutorian A. Topiramate for the treatment of infantile spasms. J Child Neurol (2006) 21:17–9. doi:10.1177/08830738060210011001

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

10. Lux AL, Edwards SW, Hancock E, Johnson AL, Kennedy CR, Newton RW, et al. The United Kingdom infantile spasms study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre randomised controlled trial. Lancet (2004) 364:1773–8. doi:10.1016/S0140-6736(04)17400-X

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

11. Lux AL, Osborne JP. A proposal for case definitions and outcome measures in studies of infantile spasms and west syndrome: consensus statement of the west Delphi group. Epilepsia (2004) 45:1416–28. doi:10.1111/j.0013-9580.2004.02404.x

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

12. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion. Epileptic Disord (2007) 9:353–412.

Pubmed Abstract | Pubmed Full Text

13. Brodie SE. Screening for vigabatrin (Sabril ®) retinal toxicity in children. Ophthalmic Genet (2011) 32:193–5. doi:10.3109/13816810.2011.574185

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

14. MacKay M, Weiss S, Adams-Webberm T, Ashwal S, Stephens D, Ballaban-Gill K, et al. Practice parameter: medical treatment of infantile spasms. Report of the American academy of neurology and the child neurology society. Neurology (2004) 62:1668–81. doi:10.1212/01.WNL.0000127773.72699.C8

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

15. Stafstrom CE, Arnason BG, Baram TZ, Catania A, Cortez MA, Glauser TA, et al. Treatment of infantile spasms: emerging insights from clinical and basic science perspectives. J Child Neurol (2011) 26:1411–21. doi:10.1177/0883073811413129

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

16. Paciorkowski AR, Thio LL, Dobyns WB. Genetic and biologic classification of infantile spasms. Pediatr Neurol (2011) 45:355–67. doi:10.1016/j.pediatrneurol.2011.08.010

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

17. Curatolo P, Moavero R. mTOR inhibitors as a new therapeutic option for epilepsy. Expert Rev Neurother (2013) 13:627–38. doi:10.1586/ern.13.49

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

18. Krueger DA, Wilfong AA, Holland-Bouley K, Anderson AE, Agricola K, Tudor C, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol (2013). doi:10.1002/ana.23960 [Epub ahead of print]

Pubmed Abstract | Pubmed Full Text | CrossRef Full Text

Citation: Pavone P, Falsaperla R, Ruggieri M, Praticò AD and Pavone L (2013) West syndrome treatment: new roads for an old syndrome. Front. Neurol. 4:113. doi: 10.3389/fneur.2013.00113

Received: 25 June 2013; Accepted: 27 July 2013;
Published online: 12 August 2013.

Edited by:

Fernando Cendes, University of Campinas, Brazil

Reviewed by:

Peter Halasz, Hungarian Sleep Society, Hungary

Copyright: © 2013 Pavone, Falsaperla, Ruggieri, Praticò and Pavone. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: lorenzo_pavone@hotmail.com